<span item_type="fundamental" item_id="1f06026e5874ca8898555dc50b13f93e" counter_id="ST/US/VERU" env="prod"></span><span item_type="announcement" item_id="594618256266824833" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 0.</p><p>EPS: As of FY2025, the actual value is USD -1.55.</p><p></p><h3>Operating Expenses</h3><ul><li>Research and development expenses increased to $15.6 million from $12.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li><li>General and administrative expenses decreased to $19.9 million from $24.6 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li></ul><h3>Operating Loss</h3><ul><li>Operating loss from continuing operations decreased to $24.8 million from $36.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss from continuing operations decreased to $15.7 million, or $1.07 per share, compared to $35.3 million, or $2.61 per share.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li><li>Net loss decreased to $22.7 million, or $1.55 per share, compared to $37.8 million, or $2.80 per share.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash, cash equivalents, and restricted cash were $15.8 million as of September 30, 2025, versus $24.9 million as of September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li><li>Net cash used in operating activities was - $30.0 million compared to - $21.7 million in the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Post fiscal year 2025, the company completed a public offering for additional net cash proceeds of approximately $23.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li><li>The FDA has provided regulatory clarity for enobosarm in combination with GLP-1 RA, with incremental weight loss as an acceptable primary endpoint for approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li><li>The Phase 2b PLATEAU clinical trial is expected to start in Q1 calendar year 2026 with interim analysis results anticipated in Q1 calendar year 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm"></span></li></ul>

Veru | 8-K: FY2025 Revenue: USD 0